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Abstract  
Objective: To provide a systematic review of economic evaluations that have been conducted for 
onchocerciasis interventions, to summarise current key knowledge and to identify research gaps. 
Method: A systematic review of the literature was conducted on the 8th of August 2018 using the 
PubMed (MEDLINE) and ISI Web of Science electronic databases. No date or language stipulations 
were applied to the searches. 
Results: We identified 14 primary studies reporting the results of economic evaluations of 
onchocerciasis interventions, 7 of which were cost-effectiveness analyses. The studies identified 
used a variety of different approaches to estimate the costs of the investigated 
interventions/programmes. Originally, the studies only quantified the benefits associated with 
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preventing blindness. Gradually, methods improved and also captured onchocerciasis-associated 
skin disease. Studies found that eliminating onchocerciasis would generate billions in economic 
benefits. The majority of the cost-effectiveness analyses evaluated annual mass drug administration 
(MDA). The estimated cost per disability-adjusted life year (DALY) averted of annual MDA varies 
between US$3 and US$30 (cost year variable). 
Conclusions: The cost benefit and cost effectiveness of onchocerciasis interventions have 
consistently been found to be very favourable. This finding provides strong evidential support for the 
ongoing efforts to eliminate onchocerciasis from endemic areas. Although these results are very 
promising, there are several important research gaps that need to be addressed as we move 
towards the 2020 milestones and beyond. 
 
Keywords: Onchocerciasis, River blindness, Economic evaluations, Cost effectiveness, Cost-benefit 
analyses, Cost, Elimination, Health economics 
 
Introduction  
Human onchocerciasis, also known as ‘river blindness’, is a parasitic infection caused by the filarial 
nematode Onchocerca volvulus. It is transmitted by the bites of Simulium blackflies. Of the 120 
million people at risk, 99% live in sub-Saharan Africa, although the disease has also been endemic in 
six countries of Latin America and is present in Yemen (1). Symptoms can include severe itching, 
disfiguring skin conditions, visual impairment, and permanent blindness (1). Onchocerciasis is the 
world’s second leading infectious cause of blindness after trachoma (2). Onchocerciasis can also 
cause excess mortality (3-5) and is associated with epilepsy, nodding syndrome and hyposexual 
dwarfism (Nakalanga syndrome) (6-8). 
During the last 40 years, there has been a remarkable expansion of onchocerciasis control 
programmes worldwide (9-14), summarized in Box 1. These programmes have had a large impact on 
reducing onchocerciasis as a public health problem. Initially, control programmes (i.e. the 
Onchocerciasis Control Programme in West Africa (OCP)) only used large-scale vector control as the 
drugs available at that time were too toxic for large-scale use. This changed in 1987, when 
ivermectin (produced under the brand name Mectizan®), a drug suitable for mass treatment, was 
registered for human use against onchocerciasis, and large-scale chemotherapeutic control 
programmes became feasible (11).  
In 1987, Merck & Co. committed to supply ivermectin to onchocerciasis endemic countries 
“as much as necessary for as long as necessary” (15, 16). Over 7.8 billion ivermectin tablets have 
been donated for the treatment of onchocerciasis and lymphatic filariasis (17). This unprecedented 
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donation allowed onchocerciasis control in endemic areas where vector control was not feasible or 
too expensive to sustain and ivermectin began to be distributed in the late 1980s. Initially, mobile 
teams of paid, local health professionals were used to distribute ivermectin; however, this was costly 
(18), and programmes mostly switched to using volunteer distributors and community-directed 
approaches (Box 1). 
Motivated by the successful elimination of the infection in some foci of Mali and Senegal 
(19, 20), there was a shift in onchocerciasis control policy in Africa, with the aim of programmes 
changing from elimination as a public health problem to elimination of transmission and ultimately 
infection. In 2012, the Joint Action Forum of the African Programme for Onchocerciasis Control 
(APOC), chaired by WHO and the ministers of health of endemic countries, set the target at 
elimination in 80% of African countries by 2025 (21). WHO’s roadmap on neglected tropical diseases 
(NTDs) also included goals for the elimination in several African countries by 2020 (22). 
The coverage of NTD mass drug administration (MDA) programmes has notably expanded 
over the last 10 years. In 2017, 1.762 billion treatments were delivered worldwide (23). NTD control 
programmes are becoming increasingly integrated, moving towards targeting multiple diseases 
within a multipronged programme (24, 25). In May 2016, the WHO launched the Expanded Special 
Project for Elimination of Neglected Tropical Diseases (ESPEN), a five-year project to provide national 
NTD programmes with technical and fundraising support to help them accelerate the control and 
elimination of NTDs amenable to preventive chemotherapy, namely onchocerciasis, lymphatic 
filariasis, schistosomiasis, soil-transmitted helminthiases and trachoma (26). The integrated and 
cross-sectorial response to NTD control is relevant to the Sustainable Development Goals, including 
among others Universal Health Coverage, Water Sanitation and Hygiene (WASH) initiatives, global 
partnerships, alleviating poverty and hunger and improving education and economic growth (27). 
The aim of this paper is to provide a systematic review of economic evaluations that have 
been conducted for onchocerciasis interventions, to summarise current key knowledge and to 
identify research gaps in this area. 
 
Methods 
Search strategy  
A systematic review of the literature was conducted on the 8th of August 2018 using the PubMed 
(MEDLINE) and ISI Web of Science electronic databases. Variants of the following search terms were 
used to find relevant papers: river blindness, onchocerciasis, cost(s), cost-benefit, cost-effectiveness, 
economic(s), economic evaluation. No date or language stipulations were applied to the searches. A 
more detailed summary of the search terms and the PRISMA checklist are supplied in Supporting 
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Information. The titles and abstracts of all the identified papers were examined initially for relevance 
and then the bibliographies of papers suitable for inclusion were scanned for studies not originally 
retrieved from the databases. The full selection process is outlined in Figure 1. Studies relating to 
cost recovery and willingness to pay were not explicitly included as an outcome of the systematic 
literature search (but are referenced within the review where relevant). 
 
Results and discussion 
We identified 14 primary studies reporting the results of economic evaluations of onchocerciasis 
interventions, which are described in Tables 1 and 2. It is important to note that both the OCP and 
APOC expanded over time (Box 1) and it was not always clear which specific countries/areas were 
being included in the different analyses.  
 
Estimated cost of onchocerciasis interventions 
A key component of any cost-benefit or cost-effectiveness analysis (Box 2) of an intervention is its 
estimated cost. The studies identified used a variety of different approaches to estimate the costs of 
the investigated interventions/programmes. Many of the studies based their costs on programme 
budgets/reports and very few were based on comprehensive costing studies/approaches. There was 
variation in what types of costs were included within the analyses.  
The estimated intervention costs tended to be higher for the studies evaluating OCP 
activities. This is likely because the control measures used by the OCP (vector control and mass 
treatment delivered via mobile teams) were more expensive than the community-directed 
treatment approach subsequently used by other programmes (28) (Box 1). The nominal financial 
cost (i.e. not adjusted for inflation or discounted) of the OCP (1974-2002) was just under US$1 billion 
(29) whereas the projected cost of the larger APOC (1995-2015) was US$478 million (30).  
Often it was difficult to compare the reported costs from the different studies, as it was not 
always clear how costs were estimated, what activities were costed, and wether reported values 
were discounted or not. Some studies appeared only to adjust the costs for inflation and not 
discount them (Box 3).  
The studies evaluating programmes using community-based mass treatment generally 
assumed delivery costs of around US$0.50 per treatment. This is consistent with the findings of a 
systematic review by Keating et al. (31), in which the average of identified onchocerciasis-specific 
cost estimates was US$0.46 per treatment, as well as with recent MDA cost benchmarks estimated 
by the WHO (32, 33). However, it is important to note that the costs of MDA delivery vary across 
different settings. An important driver in this variation is the size of the targeted population (34-36). 
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This is because MDA programmes generate economies of scale; as the number of people treated 
increases, the cost per treatment tends to decrease (37, 38). NTD control programmes have also 
become increasingly integrated and instead of using separate disease-specific programmes they now 
often target multiple diseases within one programme. This can result in economies of scope, 
reducing the overall cost of the NTD interventions (31, 37-43). Most of the studies identified did not 
consider the potential impact of economies of scale or scope on the costs of the interventions within 
their analyses.  
There are very few studies that have investigated the costs of alternative onchocerciasis 
interventions to annual community-directed MDA (with ivermectin) (32). Turner et al. (44) found 
that the yearly cost of a community-directed ivermectin treatment programme increases by 50-60% 
when increasing the treatment frequency from once to twice a year. 
Several studies also considered the potential for cost-recovery/cost-sharing, where the 
communities contribute financially to the cost of the programme (28, 45-47) and the participants’ 
willingness to pay for ivermectin treatment (48, 49). 
 
Economic costs vs financial costs 
The majority of the studies considered only the financial costs of the intervention. However, when 
performing economic evaluations of healthcare interventions, it is typically recommended to use 
“economic costs” (50, 51) (Box 2). These conceptualize costs in a broader way than do financial costs 
and represent the full value of all resources used for an intervention, including the value 
(opportunity cost) of donated resources. Economic costs are important as they reflect the 
sustainability and replicability of interventions.  
Ndyomugyenyi et al. (34) found that when accounting for the salaries of governmental 
personnel and the opportunity cost incurred by the volunteer community-directed distributors 
(CDDs – Box 2), community-directed treatment with ivermectin in Uganda cost US$0.78 per 
treatment (2004 prices). However, if these costs were excluded, the cost fell to just US$0.17 per 
treatment (2004 prices). The difference between the financial and economic costs was smaller 
(US$0.39 vs US$0.45 (2011 prices)) in a study in Ghana (44). 
A key economic cost for many MDA programmes is the value of the unpaid contribution of 
the volunteer CDDs. Turner et al. (52) found that the average economic costs relating to the 
volunteer CDDs unpaid time can be significant, varying between US$0.05-0.16 per treatment (cost 
year variable). They estimated that the time donated by volunteer CDDs to APOC (1997-2015) would 
be valued between US$60-90 million (52).  
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Economic value of ivermectin  
Some of the identified studies considered the economic value of the donated ivermectin within their 
cost-effectiveness analysis. Most used the quoted commercial value from the Mectizan Donation 
Program, i.e. US$1.50 (and US$0.0018 in shipping costs) per tablet. Assuming that, on average, a 
treatment requires 2.8 tablets, this results in an estimated average economic value of donated 
ivermectin of US$4.21 per treatment (30). Kim et al. (53) assumed a different economic value of 
US$1.5054 per treatment. Over the past 30 years, Merck & Co. has donated over 2.7 billion 
treatments of ivermectin for onchocerciasis and lymphatic filariasis (16). Based on these different 
assumed valuations of ivermectin this donation would be valued between US$4-11 billion. 
In the context of these economic evaluations, it should be noted that it is difficult to 
estimate the true economic value of a donated drug (54). This is because the manufacturing costs of 
drugs are proprietary information, and the donating company may potentially mitigate some of the 
cost through charitable tax write-offs as well as intangible benefits, such as enhanced public image 
among shareholders and employees (55). It is also argued that if ivermectin were not donated, it 
could potentially be procured from other sources at less than the proprietary cost. For example, 
Hernando et al. (55) estimate the price of an annual 9 mg ivermectin treatment with generic drugs 
on the global market (56) to be approximately US$0.78. Based on this, they estimated the direct cost 
for the tablets donated during 2005-2011 to be US$600 million, compared with the stated value of 
US$3.8 billion (55), and with potential tax write-offs their net cost could be around US$180 million 
(55).  
These arguments need to be interpreted with caution. Firstly, there is the issue of drug 
quality, which is a major challenge in low-income countries, and especially with anthelmintics and 
similar popular drugs which commonly attract counterfeit manufacturers. Secondly, the donations 
themselves have a chilling effect on the markets, driving generic prices downwards. There is in fact, 
no established way to estimate the “real” market price of these drugs, and it is notable that even the 
lowest estimates of the value of the donations are very substantial, measured in hundreds of 
millions of dollars per year. What is clear is that the ivermectin donation was the first substantial 
donation of its type, and its success led to the concept of the NTDs as solvable diseases of poverty, 
and to the massive donation of some 1.5 billion treatments for a range of NTDs by some 14 other 
pharmaceutical companies during the London Declaration (57). 
The foundation of onchocerciasis control programmes is based on the commitment of 
ivermectin donation from Merck & Co. for as long as needed (17, 57). Therefore, it is debatable 
when the value of ivermectin should be included within an economic evaluation. 
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Estimated economic benefits and cost-benefit analyses of onchocerciasis interventions  
We identified several cost-benefit analyses of onchocerciasis interventions (Table 1). The estimated 
internal rate of return (IRR - Box 2) ranged from between 11-20% for the OCP and 17-24% for APOC 
(for comparison, an IRR above 10% is considered by the World Bank as the standard for a successful 
public health programme (58)) (Table 1). The estimated net present values (NPV) were between 
US$8 million to US$3.7 billion for OCP and US$54-307 million for APOC (cost years variable). 
However, there was variation between the different studies regarding the time frame considered 
and the discount rate used (Box 3), making it difficult to compare the results directly. None of the 
cost-benefit analyses identified included the economic value of the donated ivermectin tablets in 
their base case analysis (Table 1). Waters et al. (18) highlighted that this value could outweigh the 
estimated economic benefits from both the OCP and APOC programmes. 
More recently, Redekop et al. (59) and Kim et al. (60) quantified the economic benefits 
associated with onchocerciasis elimination. Both those studies found that eliminating onchocerciasis 
would generate billions in economic benefits (Tables 1 and 3). 
The identified studies quantified three different types of economic benefits of 
onchocerciasis interventions (namely, productivity gains, land use gains and reductions in outpatient 
services and out-of-pocket expenditures), but there was variation across the studies regarding how 
and which economic benefits were quantified (Table 3). Many of the broader benefits of 
onchocerciasis in terms of the Millennium Development Goals are highlighted by Dunn et al. (61). 
 
Productivity gains 
Onchocerciasis-associated morbidity can affect an individual’s economic productivity. Lenk et al. (62) 
recently conducted a systematic review of the productivity losses related to the NTDs eligible for 
preventive chemotherapy and a summary of the studies they identified for onchocerciasis is 
presented in Table 4. Unsurprisingly, the degree of the productivity loss was dependent on the type 
of onchocerciasis morbidity. Productivity losses were highest for blindness and lowest for skin 
disease.  
A key component of estimating the economic benefits of onchocerciasis interventions is the 
productivity gains that result from preventing onchocerciasis morbidity. The cost-benefit analyses 
identified appeared to estimate only the productivity gains associated with preventing 
onchocerciasis-associated blindness. However, the productivity losses associated with 
onchocerciasis-associated skin disease and visual impairment are also significant (Tables 4 and 5). 
Consequently, only quantifying the productivity gains associated with prevented cases of blindness 
underestimates the economic benefits of onchocerciasis interventions (63). 
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In contrast, both Kim et al. (60) and Redekop et al. (59) included the productivity gains 
associated with preventing onchocerciasis-associated skin disease when quantifying the economic 
benefits of onchocerciasis interventions. Kim et al. (60) assumed that severe itching was associated 
with a 19% productivity loss and this made up 65% of their projected income/productivity gains. In 
Redekop et al.’s (59) study, the benefits associated with preventing skin disease represented 22% of 
the total projected economic benefit. This assumed that “moderate” skin disease is associated with a 
10% productivity loss and “mild” skin disease is associated with no productivity loss (Table 5). 
For these types of estimates, it is important to consider which method is used to value the 
productivity gains. Estimating the income of individuals affected by NTDs is challenging, as many of 
them are in informal employment (such as subsistence farmers). The analyses identified used a 
variety of different methods and sources to approximate the typical income of someone with 
onchocerciasis-associated morbidity (such as the per capita gross domestic product (GDP), 
subsistence wage, the GDP per capita of the lowest income quintile). In some cases, the income 
source was not clearly stated. It is important to note that different income sources can give very 
different estimates of an individual’s typical income, even when they relate to the same type of 
profession/socioeconomic status (40).  
Kim et al. (60) also considered the potential income losses of the informal caregivers of 
patients with low vision and blindness (Table 5). Currently, there are very few primary data 
quantifying this. Ibe et al. (64) found that within their survey of onchocerciasis patients in Nigeria, 
the average productivity cost among the informal caregivers was US$3.50 per month (cost year 
unavailable). 
In all studies productivity gains were estimated using the human capital approach, which 
takes the patient's perspective for valuing lost productivity. It should be noted that if the friction 
cost approach was used (which takes the employer's perspective, i.e. only counts as lost, the hours 
not worked before another employee takes over the patient’s work (65)), the estimated productivity 
gains would have been lower (66). There is continued debate within the field regarding which 
approach is most appropriate (65). In the context of studies for NTDs, it should be highlighted that 
the friction cost approach is hard to apply to populations that are predominately in informal 
employment. Kim et al. (60) and Kim & Benton (58) made adjustments for employment rates/labour 
force participation within their estimates. 
 
Land use gains 
Onchocerciasis caused many people to abandon the fertile river valleys within the countries covered 
by the OCP (2). It has been estimated that as a result of OCP interventions, 25 million hectares of 
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abandoned arable land was able to be reclaimed for settlement and cultivation (58, 67) (capable of 
feeding 17 million people annually (67, 68)). Several of the cost-benefit analyses of the OCP included 
the projected economic benefits resulting from the increased agricultural output from the reclaimed 
land. These estimates varied between US$57-205 million (cost years variable) and were sensitive to 
the assumed time horizon and the discount rate (Table 3). The estimate from Kim & Benton (58) was 
even higher but the specific value was not stated (the NPVs (1974-2012) relating only to land use 
gains ranged between US$3,154 million (using a 3% discount rate) and US$380 million (using a 10% 
discount rate)). It should be highlighted that such calculations are based on various assumptions 
surrounding rates of agricultural land use and repopulation of the reclaimed areas (Table 3). It is also 
important to consider that onchocerciasis may not have been the sole cause of depopulation of 
these areas (9). Because the same level of abandonment of river valleys was rarely seen in non-OCP 
countries (63), the analyses of the countries covered by APOC generally did not include the 
economic benefits related to land-use gains. One exception is the report by Haddix (69), which is 
reported to have re-evaluated APOC interventions including the estimated economic benefit 
resulting from increased agricultural output (Table 4). 
 
Outpatient services and out-of-pocket expenditure 
Individuals with onchocerciasis-associated morbidity may seek care from their local health services. 
Kim et al. (60) projected the economic benefits of onchocerciasis elimination resulting from the 
decreased use of outpatient health services. They estimated that between 2013 and 2045, when 
compared with a control scenario, the elimination of onchocerciasis in Africa would save the health 
systems US$35.9-38.6 million in outpatient service costs, and save the patients/households US$24.7-
26.0 million in out-of-pocket payments (2013 prices) (60). Primary data on these costs or on how 
often individuals with onchocerciasis seek outpatient care or use local health services are scarce. An 
exception is the study by Ibe et al. (64), which found that the average direct cost incurred by 
onchocerciasis patient’s per outpatient visit was US$14.00 (cost year unavailable), with the majority 
of this being for medications. 
Interestingly, a study conducted by the World Bank and WHO reported that on average, 
people suffering from the manifestations of onchocerciasis-associated skin disease were found to 
spend an additional US$8.10 (cost year unavailable) on health-related expenditures over a six-month 
period compared with those from the same community without these manifestations (70). 
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The cost-effectiveness analyses of onchocerciasis interventions 
We identified seven studies performing cost-effectiveness analyses of onchocerciasis interventions. 
The majority of the studies evaluated annual MDA (Table 2). As with the cost-benefit analyses, 
variation in the time frames and discount rates used (Box 3) make it difficult to compare directly 
some of the results.  
Many older studies have used “healthy life years averted” as their effectiveness metric 
(which was based on reductions in the number of onchocerciasis-related blindness cases). These 
studies generally assumed that blindness results in complete disability, and that each year lived with 
blindness is equal to one full healthy life year lost, i.e. they assumed a disability weight of 1, which is 
equivalent to death (Table 5). One exception to this was Evans et al. (71), who used a lower disability 
weight for blindness of 0.5 (based on empirical evidence that blindness does not result in complete 
disability and that blind people are active both socially and economically). These studies did not 
appear to quantify the averted burden of other types of onchocerciasis morbidity (such as skin 
disease) (Table 5).  
More recent studies have used disability-adjusted life years (DALYs) averted, a standardised 
and more comprehensive effectiveness metric. The estimated cost per DALY averted of annual MDA 
varies between US$3 and US$30 (cost year variable). In comparison. the cost per DALY averted for 
the MDA delivered within the Global Programme to Eliminate Lymphatic Filariasis was estimated to 
be US$24 when using financial costs and US$64 when using economic costs (including the value of 
the donated drugs) (54). The cost-effectiveness of onchocerciasis MDA is also very favourable 
compared to other interventions conducted in low- and middle-income countries (a comprehensive 
list of cost-effectiveness estimates for a range of health interventions in these settings is provided 
within Horton et al. (72)). 
The most favourable cost-effectiveness estimates relate to interventions in savannah 
settings (73). It is important to note that these estimates are not directly generalisable to 
onchocerciasis interventions in forest areas, where ocular pathology and morbidity is considered to 
be rarer (Figure 2) (but see (74)). According to this assumption, intervention cost-effectiveness in the 
latter areas would be lower. It should be noted that this assumption is based on limited data from 
forest settings (Figure 2). 
 
The estimated cost-effectiveness ratio was also dependent on the assumed pre-control 
endemicity level, with the cost per DALY averted being lower in higher endemicity settings. In the 
long term, this range is narrower than might be expected as, although fewer DALYs are averted in 
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lower endemicity settings, the total cost of the intervention is also lower (as fewer treatment rounds 
will be needed to achieve a similar degree of control or to reach elimination) (Table 2). 
The majority of studies have taken the healthcare providers perspective, which does not 
consider the costs falling on those outside of the healthcare sector. All the cost-effectiveness 
analyses appeared to consider only the cost of the intervention, i.e. none of them included potential 
savings to outpatient services, prevented out-of-pocket costs, or productivity gains that result from 
prevented morbidity. Only a few identified studies considered the economic value of the donated 
ivermectin. Including this significantly increases interventions estimated cost and, therefore, 
decreases the estimated cost-effectiveness. For example, Turner et al. (54) found that the estimated 
cost per DALY averted increased from US$3-15 to US$29-133 (2012 prices) when including the 
economic value of donated ivermectin (which would still be classed as cost effective). It is also 
debatable when the value of ivermectin should be included within an economic evaluation, 
particularly under the healthcare providers perspective.  
Numerous approaches have been used to quantify the effectiveness of onchocerciasis 
interventions. Many older studies based the effectiveness on reductions in the incidence of 
blindness on limited empirical data and projected similar putative reductions with continuing 
intervention. More recent studies have used mathematical transmission models to project the 
ongoing future effectiveness of interventions more accurately, explicitly modelling disease dynamics 
through time (75). The two main models used for this purpose (EPIONCHO and ONCHOSIM) are 
described in Basáñez et al. (76). An important advantage of this approach is the capacity to account 
for the indirect benefits/herd effects of interventions (the indirect benefit afforded to individuals not 
directly targeted by an intervention that arises from the population-wide reduction in transmission) 
(75). These models can also account for longer time horizons, accounting for the continued benefits 
of interventions even after the control programme has stopped. 
 
DALY calculations 
DALYs are calculated as the sum of two components; the years of healthy life lost due to disability, 
and the years of life lost due to premature mortality (77). In a DALY calculation, the years of healthy 
life lost due to disability are calculated using standardised disability weights, ranging between 0 and 
1. This reflects the severity of the different disease sequelae, with 0 representing perfect health and 
1 representing death. The disability weights used for onchocerciasis DALY calculations have changed 
over time (Table 5).  
For the 2010 GBD study, the disability weights for vision loss were notably decreased 
compared to previous studies, whereas the weights for skin disease were increased (Table 5). 
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Consequently, Coffeng et al. (78) found that when using the newer weights, the estimated number 
of DALYs averted by APOC (2000-2015) increased by 9% compared to when using the GBD 2004 
weights. Moreover, skin disease, instead of eye disease, became the most important contributor to 
the burden of onchocerciasis. Since the GBD 2010 study, onchocerciasis-associated skin disease has 
not been assigned a specific single disability weight, and more general disfigurement health states 
(stratified by three severity levels and whether or not the disfigurement is associated with itch or 
pain) are used. When using these updated GBD disability weights, studies have typically estimated 
an overall average skin disease weight (Table 5). Subsequent GBD studies have made additional 
changes to the DALY calculation for onchocerciasis, particularly relating to the weights attributed to 
the different types of skin disease and the types of skin disease included (79). A more detailed 
overview of the changes to the GBD study methodology used to calculate DALYs is presented in (80-
82).  
Several studies have accounted for the excess mortality associated with onchocerciasis 
visual morbidity (3) within their DALY calculations. However, it has generally not been considered 
that irrespective of visual morbidity, there is an increased risk of mortality associated with increasing 
microfilarial load, particularly in children and young adults aged below 20 years (4, 5). Estimates of 
onchocerciasis burden (and the cost-effectiveness of its control) would generally increase if this 
onchocerciasis-associated excess mortality were taken into account. For example, Turner et al. (83) 
found that, depending on the pre-control endemicity level, excess mortality accounted for 29-43% of 
the estimated pre-control DALY burden of onchocerciasis. If this had not been included, the 
estimated cost-effectiveness would have been reduced substantively.  
 
Cost-effectiveness thresholds  
In cost-effectiveness analyses, the cost per DALY averted is compared to a willingness to pay 
threshold to determine whether an intervention is cost effective. However, the most appropriate 
cost-effectiveness thresholds are debated and remain somewhat arbitrary (84-86). The cost-
effectiveness threshold set by the WHO-CHOICE (87) (a cost per DALY averted < 3 times the 
country’s GDP per capita) is now considered to be too high (84-86, 88, 89). Most analyses within the 
NTD field have not used it (40, 41, 90), many opting instead for the more conservative cost-
effectiveness threshold set by the World Bank (91) (≤ US$251 per DALY averted, when adjusted for 
inflation to 2016 prices (92)). Interestingly, recent analyses have indicated that a cost-effectiveness 
threshold closer to < ½ the country’s per capita GDP would be more appropriate for low-income 
countries (88, 93). For comparison, the Disease Control Priorities project (Third Edition) used a 
threshold of US$200 per DALY averted to identify priority interventions for consideration in low-
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income countries (94). Despite this ambiguity on cost-effectiveness thresholds, onchocerciasis 
interventions would remain classed as cost effective by any of the proposed measures. 
 
Elimination and evaluation of alternative interventions  
Traditional cost-effectiveness analyses of new interventions evaluate their incremental effectiveness 
and incremental cost compared to the current practice (calculating incremental cost-effectiveness 
ratios, Box 2). This framework has been widely and successfully used to evaluate the comparative 
cost-effectiveness of new intervention strategies for disease control. However, this incremental cost-
effectiveness framework is less informative and somewhat ill-suited for disease elimination or 
eradication programmes. For example, Turner et al. (73) found that that increasing the treatment 
frequency of ivermectin distribution from once to twice per year yielded very small incremental 
health gains (only a 3-4% increase in the number of DALYs averted) but could have a large influence 
on a programme’s overall total cost and duration (Table 2). In such cases, where an intervention is 
aimed at accelerating and sustaining elimination, an incremental cost-effectiveness ratio may not 
reflect its true value. Instead, as applied in Turner et al., the absolute cost of the intervention and 
the time it takes to achieve the desired elimination goal can be more informative. The same 
framework was applied to an economic evaluation of moxidectin (95) (Table 1), a newly-registered 
treatment for onchocerciasis (https://www.medicinesdevelopment.com/news-180613.htm). Kastner 
et al. (96) have also highlighted that the number of DALYs averted may not fully capture the long-
term consequences and broader benefits of disease eradication programmes. 
Another important aspect to consider when evaluating elimination programmes is the time 
horizon of the analysis (40). This is because the costs of elimination programmes are typically higher 
than would be needed for disease control (97). After elimination is certified, the estimated cost-
effectiveness of an elimination programme will steadily increase as the discounted benefits continue 
to accumulate but the costs have stopped (with the potential exception of ongoing surveillance). The 
benefits and potential future cost savings resulting from achieving elimination/eradication are not 
infinite (40, 73), as the costs/cost savings being considered must be restricted within a suitable time 
horizon and are typically discounted into the future (Box 3). In contrast, for disease control 
programmes, the intervention costs will typically be incurred for the full- time horizon. Because of 
this, elimination programmes can be cost-saving in the long term. However, it can take time for the 
longer-term benefits and cost savings associated with achieving elimination to outweigh the initial 
increases in costs associated with achieving elimination. Consequently, with short-term time 
horizons, elimination programmes are unlikely to be more cost effective than disease control 
programmes.  
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Eradication investment cases have been developed for a number of NTDs (98), including 
onchocerciasis (53, 60, 99). These latter studies have compared onchocerciasis control and 
elimination/eradication scenarios and have quantified the duration of the programme, its financial 
and economic cost, the number of ivermectin treatments required, the workload of the community 
healthcare workers/volunteers, costs related to outpatient healthcare services, and the productivity 
gains resulting from preventing onchocerciasis-associated morbidity. The overall conclusions of 
these studies are that eradication and elimination of onchocerciasis are both justifiable on both cost-
effectiveness and benefit-cost analysis grounds, and that eradication tends to be more favoured 
over the long-term time horizon. 
 
Sensitivity analysis  
The majority of identified studies either did not perform a sensitivity analysis or undertook only a 
univariate analysis, changing one parameter at a time to evaluate its impact independent of other 
parameters. The main exceptions to this were Redekop et al. (59) and Kim et al. (60). 
Redekop et al. (59) performed probabilistic sensitivity analysis (PSA) in which the values of 
three input parameters (the estimates of disease prevalence in 2010, the percentage of productivity 
loss/the amount of out-of-pocket payments, and the patient’s income) were allowed to vary 
simultaneously. Kim et al. (60) first conducted a one-way deterministic sensitivity analysis to 
examine which parameters are key drivers. They then conducted PSA to assess the robustness of the 
results to the joint uncertainties around all selected parameters (60).  
 
Limitations of this analysis 
A potential source of bias of the search strategy is that it did not capture economic evaluations 
published outside of the searched electronic databases (i.e. grey literature such as policy 
documents/reports, and many non-English language publications etc.). Efforts were made to 
minimise this bias by searching the bibliographies of selected studies. There could also be a degree 
of publication bias, with economic evaluations with negative or unfavourable results less likely to be 
published. It should be noted that the selection of studies was not performed independently by two 
researchers. 
 
Areas of further research 
The results of the systematic review highlight that the standard onchocerciasis control strategies are 
consistently found to be very cost effective. However, there are some important research gaps that 
need further research. 
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Data on intervention costs and the economic burden of onchocerciasis 
The costs of MDA delivery have been shown to vary across different settings (31, 32, 37, 41, 100). 
This variation potentially affects the generalisability of any cost-effectiveness/cost-benefit analysis 
(75), and future studies need to quantify the impact of this in greater detail. It should be noted that 
the costs of conducting MDA in areas where onchocerciasis and loiasis are co-endemic may be 
higher – due to the need for enhanced surveillance and community sensitization.  
In addition, further studies are needed to investigate how integrating NTD control 
programmes (31, 39) may influence the costs/cost-effectiveness of implementing different control 
strategies (37, 40). There is notable variation in the methodological approaches used to quantify the 
economic costs incurred by CDDs. It would be beneficial if future studies adopted more consistent 
approaches (outlined in (52)). 
The cost of onchocerciasis control programmes will likely increase significantly as they 
approach the “last mile” towards elimination (37). This is partly because of the increase in the costs 
resulting from expanding the programmes to target harder-to-reach areas/groups (diseconomies of 
scale) (37). This is an important issue for NTD programmes in general, and further costing studies are 
needed to quantify it. 
Further studies are needed on quantifying the medical costs incurred by those with 
onchocerciasis seeking treatment. Such studies could yield more robust estimates of the economic 
benefits of onchocerciasis control (60). It would also be beneficial if future studies sought to quantify 
the productivity losses incurred by informal caregivers, not just those caring for the blind. Note also 
that with the rise in sophistication of health systems in the endemic countries, the health system 
costs and the contribution of out-of-pocket expenses are both likely to rise (101). 
Our analysis also revealed that studies used cost data collected in different years, but it was 
not always clear if and how costs were adjusted for inflation. Future studies should report this more 
explicitly (102) and within a given study the costs would be standardised to a consistent year. 
 
Economic evaluations of alternative interventions  
In certain epidemiological and programmatic circumstances, alternative strategies to annual MDA 
will be required to achieve the current goals for onchocerciasis control/elimination (21, 22, 103). 
Such strategies include increased frequency of MDA (up to four times per year), localised low-cost 
vector control and treatment strategies using moxidectin, anti-Wolbachia therapies and new 
macrofilaricidal drugs (104-106). However, there currently are very few costing studies and 
economic evaluations relating to these alternative interventions (32, 107). Studies are needed to 
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evaluate the cost and cost-effectiveness of such strategies. When such studies are performed, it will 
be vital that the generalizability of the estimated cost across different programmatic settings is 
considered (37). It will also be important to consider the value of these alternative interventions not 
only in reducing the disease burden where they are implemented, but also in their capacity to help 
eliminate onchocerciasis more quickly. This will be particularly important in reducing the risk that 
‘hot spots’ of sustained transmission seed and re-establish transmission in areas where 
onchocerciasis has been eliminated. 
This area of research is particularly important for interventions targeting onchocerciasis in 
Loa loa co-endemic areas. It has been recently predicted that, at the 2025 horizon, two-thirds of 
onchocerciasis remaining cases will be living in hypoendemic areas for onchocerciasis where the risk 
of Loa-related post-ivermectin severe adverse events (SAEs) has so far been considered to outweigh 
the benefits for the communities. The paradigm shift from control to elimination implies that 
hypoendemic areas start receiving community treatment with ivermectin. A test-and-not-treat 
strategy for onchocerciasis has recently been successfully piloted in a health area of Central 
Cameroon where community-directed treatment with ivermectin had to be permanently halted 
after a series of SAEs occurred in 1999 (108). Costing studies of this approach are ongoing. Critical 
questions when addressing the cost-effectiveness of this intervention include the counterfactual - 
what it would cost to leave all those populations untreated? – and cost-effectiveness relative to 
other locally important health issues. 
Future economic analyses of alternative interventions need to be tailored to the key policy 
questions from the different decision makers and stakeholders. These different questions may 
require different methodological approaches and perspectives for the analyses. This further 
emphasizes the need for transparent reporting of methodology in economic evaluations. 
 
Quantifying the health benefits of interventions 
Many older studies only quantified the health and economic benefits resulting from the number of 
blindness cases averted. More advanced disease models have been developed that account for 
averted visual impairment, skin disease, and excess human mortality. However, further refinements 
are needed to better capture the relationship between infection and skin disease (109), and to 
account for related neurological disorders such as epilepsy and nodding syndrome (6-8).  
 
When evaluating an intervention aimed at reducing morbidity, the number of DALYs averted 
is often the best effectiveness metric, as it allows cost-effectiveness estimates to be directly 
compared to estimates relating to other interventions/diseases as well as to standardised cost-
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effectiveness thresholds. This makes the results of economic evaluations easier to interpret by 
policymakers. However, DALYs do have limitations and there are controversies surrounding their 
calculation (110). For example: 
 The universal disability weights do not account for how the local context may influence the 
burden of a disease. Consequently, the potential that the burden of a disease or its sequelae may be 
worse for those that are living in poverty is not accounted for. It has been argued that this aspect of 
DALY calculations may significantly underestimate the burden of poverty-related diseases (110, 111).  
 The DALY disability weights do not fully account for the psycho-social implications of a 
disease or its sequelae (112) and its overall impact on quality of life. They also do not explicitly 
account for the impact of the disease on patients’ informal caregivers. In particular, the updated 
disability weight for blindness (decreasing from 0.60 to 0.19) has been controversial within the field 
(113, 114). A possible reason for this significant change is that within the updated GBD framework 
(post-GBD 2010), the disability weights are intended to be solely measures of losses of ‘optimal 
health’ and are not intended to represent losses of well-being/welfare (80, 115). 
 
Interestingly, the same age group (those aged below 20 years) for which there is a statistically 
significant higher risk of mortality for a given microfilarial load in comparison to those aged 20 years 
and older (5), is the group with the onset and higher incidence of nodding syndrome, a type of 
epilepsy that is increasingly recognised as associated with onchocerciasis (116, 117). Preliminary 
studies of the disease burden of onchocerciasis-associated epilepsy have been conducted (118). 
These studies should be followed by economic evaluations of both onchocerciasis-associated 
epilepsy and the impact of onchocerciasis interventions. 
 
Joint/auxiliary benefits 
Ivermectin is a broad-spectrum antiparasitic drug that also has an impact on other co-endemic 
parasitic infections (such as soil-transmitted helminthiases, lymphatic filariasis, loiasis and scabies). 
Krotneva et al. (119) assessed the auxiliary benefits of APOC and estimated that between 1995 and 
2010, ivermectin mass treatment (in APOC regions) cumulatively averted approximately 500,000 
DALYs from co-endemic soil-transmitted helminth infections, lymphatic filariasis, and scabies. This 
highlights that the overall cost-effectiveness of onchocerciasis interventions may be even higher 
than previously reported. Further quantification of these auxiliary benefits would be useful to 
improve estimations of the impact of onchocerciasis interventions.  
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Modelling and elimination thresholds 
Dynamic transmission models have an important role, particularly for the evaluation of novel 
interventions and how they compare to the standard strategy of MDA with ivermectin. These 
models (reviewed in Basáñez et al. (76)) have undergone extensive refinement in recent years to 
better capture parasite population dynamics during interventions (120) and to produce more robust 
projections on the likelihood of elimination. These modelling efforts will be particularly useful in 
identifying epidemiological and programmatic circumstances in which alternative strategies will be 
required to reach elimination (for example in highly endemic settings, settings with suboptimal 
responses to ivermectin (121, 122), or where the initiation of programmes has previously been 
delayed (103)). Moreover, transmission models (as opposed to so-called ‘static’ models) capture 
explicitly our current understanding of the changing parasite dynamics during interventions (75).  
 
Conclusions 
The cost benefit and cost effectiveness of onchocerciasis interventions have consistently been found 
to be very favourable. This finding provides strong evidential support for the ongoing efforts to 
eliminate onchocerciasis from endemic areas.  
MDA against other NTDs has also been found to be cost effective (40, 54, 90) and, therefore, 
a logical next step would be to quantify the net cost-effectiveness of more closely integrating these 
programmes, which are already often running side-by-side in co-endemic areas. Indeed, the primary 
rationale for the aggregation of common infectious diseases of the poor under the denomination of 
“Neglected Tropical Diseases” was the perception that treating many diseases using a single 
common delivery system would be inherently cost effective. It would be important to future policy 
making to explore the evidence base for that perception. Further systematic reviews of this type on 
other NTDs would also be useful. 
We identify three main research gaps in this area. First, the need to be more inclusive in 
quantifying burden. Originally, studies only quantified the benefits of preventing blindness, and then 
also captured onchocerciasis-associated skin disease. An improved understanding of other factors, 
such as onchocerciasis-associated epilepsy (117, 118) would enhance the precision of the calculated 
benefits. Second, the evaluation of interventions targeting Loa loa co-endemic areas which will 
become more important in the end-game for elimination. Finally, the need to increase the 
comparability of economic analyses. Greater adherence to standardised guidelines for reporting the 
results of economic evaluations (such as CHEERS for cost-effectiveness analysis (123)) would be 
beneficial and increase the reliability and reproducibility of reported findings.  
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Programmes to eliminate onchocerciasis have always been in the vanguard of global efforts 
to eliminate diseases of poverty. Lessons learned here from the economic analysis of onchocerciasis 
programmes have direct relevance to the design of programmes addressing all the other NTDs.  
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leTable 1. Summary of the identified cost-benefit analyses and estimates of the economic benefits of onchocerciasis interventions Source Setting and 
time period of 
the 
intervention 
Time 
horizon 
for the 
benefits  
Discoun
t rate 
Cost 
year 
Cost of the intervention Total economic benefita Net present value Interna
l rate 
of 
return 
Benton 
& 
Skinner 
(67) 
OCP (1974-
2004) 
1974-
2023 
5-10% 1985 
US$ 
•US$140 million (10% discount rate) to 
US$231 million (5% discount rate).  
•US$437 million when not discounted. 
•Financial costs from the programmes 
perceptive. 
•Details not specified. 
US$148 million (10% discount 
rate) to US$543 million (5% 
discount rate). 
 
US$8 million (10% 
discount rate) to 
US$312 million (5% 
discount rate). 
11–
13% 
Kim & 
Benton 
(58) 
OCP (1974-
2002) 
1974-
2012 
 
3-10% 1987 
US$ 
 
•US$571.2 million (appears to be pre-
discounting). 
•Financial costs from the programmes 
perceptive. 
•Based on actual and projected OCP 
expenditure. 
Not stated. US$485 million (10% 
discount rate) to 
US$3,729 million 
(3% discount rate). 
20% 
 
 
McFarla
nd & 
Murray 
(124)† 
OCP (10-year 
project time 
period) 
1974-
2023 
5% Not 
availab
le 
 
•US195.5 million (not discounted). 
•Details not available. 
Not available. US$8 million. - 
Benton 
(125) 
APOC (1996-
2007) 
 
1996-
2017 
10% 1996 
US$  
•US$131.2 million (appears to be pre-
discounting). 
•Financial costs from the healthcare providers 
perceptive. 
•Details not specified. 
Not stated. US$53.7 million. 
 
17% 
Haddix 
(69)† 
APOC (1996-
2007) 
 
1996-
2017 
3-10% 1996 
US$ 
•US$108.5 million (unclear if discounted). 
•Details not available. 
Not available. US$87.6 million 
(10% discount rate) 
to US$307.4 million 
(3% discount rate). 
24% 
This article is protected by copyright. All rights reserved. 
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Kim et 
al. (60) 
 
Potential 
benefits of 
achieving 
elimination 
scenarios in 
Africa 
2013-
2045 
3% 2013 
US$ 
NA 
 
Compared with the control 
scenario, the Elim I and II 
scenariosb would generate 
US$5.96 (2.53-7.28) billion 
and US$6.46 (2.83-8.09) 
billion in economic benefits 
respectively. 
NA 
 
NA 
 
Redekop 
et al. 
(59) 
Potential 
economic 
benefits of 
achieving the 
WHO 2020 
targets 
 
2011-
2030 
3% 2005 
US$ 
 
NA US$3.3 (2.4-5.11) billion. 
 
NA 
 
NA 
 
Turner 
et al. 
(95) 
Potential 
impact of 
moxidectin on 
onchocerciasis 
elimination in 
African 
savannah 
settingsc 
50 years 3% 2012 
US$ 
 
•Moxidectin distribution was assumed to cost 
the same as that for ivermectin. 
•The relative total cost of using moxidectin vs. 
ivermectin was considered for different 
programmatic scenarios c. 
•Used the healthcare providers perspective 
(not including the value of the donated drugs). 
Based on a costing study in Ghana (44). 
Annual moxidectin treatment 
would achieve similar 
reductions in programme 
duration as using biannual 
ivermectin treatment.  
If the moxidectin tablets 
were donated its use would 
lead to substantial in-country 
cost savings. 
NA NA 
† Information for this study was taken from Waters et al. (18).  
a The estimated economic benefits are outlined in further detail in Table 3. 
b The Control, Elim I and Elim II scenarios are described in Kim et al. (99).  
c Assumed that MDA would be stopped (determining the programme duration) once the pOTTIS would have been achieved (defined as the modelled microfilarial prevalence 
being less than 1.4%, measured just before the next treatment round).  
APOC: African Programme for Onchocerciasis Control, NA: Not applicable, OCP: Onchocerciasis Control Programme in West Africa. pOTTIS: Provisional operational thresholds 
for treatment interruption followed by surveillance. 
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Table 2. Summary of the identified cost-effectiveness analyses of onchocerciasis interventions 
Study  Setting and 
time period 
of the 
intervention 
Time 
horizon 
for the 
benefits 
Discoun
t rate 
Cost 
year 
Cost of the intervention Effectiveness  Cost-effectiveness ratio 
McFarlan
d & 
Murray 
(124)† 
OCP 
 
- - Not 
availabl
e 
 
•US$19.5 million per year. 
•Details not available. 
•640 000 DALYs lost annually in absence 
of control. 
•Details not available. 
•If all of the onchocerciasis 
related DALYs were eliminated, 
the programme would cost 
US$30.47 per DALY averted. 
Prescott 
et al. 
(126) and 
Prost & 
Prescott 
(127) 
OCP - Upper 
Volta (now 
Burkina 
Faso) 
(1975-1994) 
1975-
1994 
10% 1977 
US$ 
 
•US$22.1 million. 
•Financial costs from the 
programmes perceptive. 
•Based on actual and projected 
OCP expenditure. 
•147,294 healthy life-years added. 
•Based on the estimated number of 
blindness cases prevented.  
•Assumed that one blindness case 
results in 23 years healthy life lost in 
hyperendemic and 20 in mesoendemic 
areas.  
•Assumed that blindness is associated 
with a disability weight of 1. 
•US$150 per healthy life-year 
added. 
•When not discounting the 
effectiveness, the results 
changed to US$20 per healthy 
life-year added. 
Evans et 
al. (71) 
OCP - 
Burkina Faso  
(1974-1997) 
1974-
1997 
10% 
(but 
varied 
between 
3-15%) 
1984 
US$ 
 
•US$115 million (appears to be 
pre-discounting). 
•Financial costs from the 
programmes perceptive.  
•Based on actual and projected 
OCP expenditure. 
•21,567 healthy life-years added.  
•Based on the estimated number of 
blindness cases prevented.  
•Assumed that one blindness case 
results in 18.7 years healthy life lost in 
hyperendemic and 15 in mesoendemic 
areas.  
•Assumed that blindness is associated 
with a disability weight of 0.5. 
•US$2,119 per healthy life-year 
added (10% discount rate). 
•When using a 3% discount rate 
the results changed to US$1,028 
per healthy life-year added. 
 
 
 
 
Benton 
(125) 
APOC (1996-
2007) 
1996-
2017 
3% 1996 
US$ 
 
•US$131.2 million (not clear if 
the costs were discounted). 
•Financial costs from the 
healthcare providers perceptive.  
•Details not specified. 
•9,788,304 health life-years added. 
•Based on the estimated number of 
blindness cases prevented.  
•Assumed each case of blindness results 
in 20 discounted healthy life-years lost.  
•Assumed that blindness is associated 
with a disability weight of 1. 
•US$13.4 per healthy life-year 
added. 
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Coffeng 
et al. (30) 
APOC (1995-
2015) 
1995-
2015 
0% Nomina
l values 
•US$478 million. 
•Financial costs from the 
programmes perceptive.  
•Based on APOC financial reports 
for the World Bank. 
•17.4 million DALYs averted (not 
discounted). 
•Estimated using a dynamic 
transmission model (ONCHOSIM).  
•Used the GBD 2004 disability weights 
(Table 5). 
•US$27 per DALY averted. 
 
 
 
Remme 
et al. (63) 
APOC (over 
15 years) 
Over a 
25-year 
period 
Unclear Not 
stated 
•US$209 million.  
•Financial cost from the 
healthcare providers perceptive.  
•Source not stated. 
•At least 26 million DALYs averted.  
•Estimated using a back of the envelope 
calculation. 
•Details on the DALY 
calculation/weights not given. 
•Approximately US$7 per DALY 
averted. 
 
 
Turner et 
al. (73) 
Annual MDA 
in an African 
savannah 
setting (up 
to 50 
years)a, b 
 
50 years 3% 2012 
US$ 
 
•US0.55-1.07 million per 100,000 
– depending on the assumed 
endemicity levelb. 
•Assumed that once the pOTTIS 
was achieved, MDA would be 
stoppeda. 
•Economic cost from the 
healthcare providers perspective 
(not including the value of the 
donated ivermectin).  
•Based on a costing study in 
Ghana (44). 
•37,858-331,632 DALYs averted per 
100,000 –depending on the assumed 
endemicity levelb. 
•Estimated using a dynamic 
transmission model (EPIONCHO). 
•Used the GBD 2004 disability weights 
(Table 5). 
•Included the excess mortality 
associated with heavy infections (83). 
•US$3-15 per DALY averted – 
depending on the assumed 
endemicity levelb. 
•Results changed to US$29-133 
per DALY averted when 
including the additional 
economic value of the donated 
ivermectin. 
•If elimination not achieved the 
results for the lowest endemicity 
setting would change from 
US$15 to US$28 per DALY 
averted. 
Turner et 
al. (73) 
Biannual 
MDA in an 
African 
savannah 
setting (up 
to 50 
years)a, b 
 
50 years 3% 2012 
US$ 
 
•US$0.63-1.20 million per 
100,000 – depending the 
assumed endemicity levelb. 
•Incremental to annual 
treatment:  
US0.07-0.13 million per 100,000. 
•Assumed that once the pOTTIS 
was achieved, MDA would be 
stoppeda. 
•Economic cost from the 
healthcare providers perspective 
•38,585-342,229 DALYs averted per 
100,000 –depending the assumed 
endemicity levelb. 
•Incremental to annual treatment: 727-
10,597 per 100,000. 
•Estimated using a dynamic 
transmission model (EPIONCHO). 
•Used the GBD 2004 disability weights 
(Table 5). 
•Included the excess mortality 
associated with heavy infections (83). 
•Incremental cost-effectiveness 
ratio: US$12-100 per 
incremental DALY averted – 
depending on the assumed 
endemicity levelb. 
•Results changed to US$334-
2,674 per incremental DALY 
averted when including the 
additional economic value of the 
donated ivermectin. 
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(not including the value of the 
donated ivermectin).  
•Based on a costing study in 
Ghana (44). 
† Information for this study was taken from Waters et al. (18). 
 a Assumed that MDA would be stopped (determining the programme duration and its total cost) once the pOTTIS would have been achieved (defined as the modelled 
microfilarial prevalence being less than 1.4%, measured just before the next treatment round).  
b Three different endemicity levels were explored (ranging between 40-80% microfilarial prevalence). 
APOC: African Programme for Onchocerciasis Control, DALY: Disability-adjusted life years, MDA: Mass drug administration, Nominal cost: Values have not been adjusted for 
inflation, OCP: Onchocerciasis Control Programme in West Africa, pOTTIS: Provisional operational thresholds for treatment interruption followed by surveillance.  
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Table 3. Summary of the estimated economic benefits of onchocerciasis interventions relating to productivity gains and land gains  
Source Setting and time 
period of the 
intervention 
Time 
horizon for 
the 
benefits  
Cost 
year 
Value of the productivity gainsa Value of land gains 
Benton & 
Skinner 
(67) 
OCP (1974-2004) 
 
1974-2023 1985 
US$ 
•US$91 million (10% discount rate) to US$338 million (5% 
discount rate). 
•Assumed that blindness results in complete loss of 
productivity. 
•The productivity gains were valued at a subsistence wage 
of US$150 per year. 
•US$57 million (10% discount rate) to US$205 
million (5% discount rate). 
•Assumed 15 million hectares of new land made 
available. 
•Assumed that new land would be settled at a 
rate of 3% per year, beginning five years after the 
programme started in the relevant area. 
 
Kim & 
Benton 
(58) 
OCP (1974-2002) 1974-2012 
 
1987 
US$ 
 
•Values not stated. 
•Assumed that each case of blindness averted results in 20 
years of productive life gained.  
•Assumed 85% labour force participationb. 
•The productivity gains were valued based on the 
“Agriculture value-added factor cost” statistic.  
 
•Values not stated (but land related benefits 
accounted for the majority of the study’s 
estimated economic benefits). 
•Assumed 25 million hectares of new land made 
available.  
•Assumed 85% agricultural output b and that new 
land utilization would follow an S-Curve pattern 
beginning after eight years of OCP intervention. 
McFarlan
d & 
Murray 
(124)† 
 
OCP (10-year 
project time 
period) 
1974-2023 Not 
availab
le 
•US$75 million annually (unclear if discounted). 
•The productivity gains were valued assuming annual 
wages of US$150. 
•US$205 million (5% discount rate). 
•Details not available. 
Benton 
(125) 
APOC (1996-2007) 
 
1996-2017 1996 
US$  
•Values not stated. 
•The productivity gains for each case of blindness 
prevented were valued at US$150 (unclear if this is the total 
per case or per productive year). 
 
- 
Haddix 
(69)† 
APOC (1996-2007) 
 
1996-2017 1996 
US$ 
•Values not available. 
•Details not available. 
 
 
•Values not available. 
•Measured as the increase in agricultural output 
made available by increased productive labour. 
•Details not available. 
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Kim et al. 
(60)c, d 
 
Potential benefits 
of achieving 
elimination 
scenarios in Africa 
2013-2045 2013 
US$ 
•Compared with the control scenario, the Elim I and II 
scenariosd would generate US$5.9 (2.5-7.2) billion and 
US$6.4 (2.8-8.0) billion in productivity gains respectively 
(3% discount rate). 
•The productivity gains were valued based on the GDP per 
capita and were adjusted for employment rates.  
 
- 
Redekop 
et al. (59) 
Potential 
economic benefits 
of achieving the 
WHO 2020 targets 
 
2011-2030 2005 
US$ 
 
•US$3.3 (2.4-5.11) billion (3% discount rate). 
•22% due to averted skin disease and 78% from averted 
visual morbidity). 
•The productivity gains were valued based on the GDP per 
capita of the lowest income quintileb. 
- 
† Information for this study was taken from Waters et al. (18). 
a Further detail regarding how the productivity gains were calculated are provided in Table 5. 
b Assumption varied in the sensitivity analysis. 
c Also quantified the savings to the health systems and households (out-of-pocket payments) resulting from decreased usage of outpatient health services (Elim I: US$60.6 
(30-80.7) million, Elim II: US$64.6 (31.8-86.4) million - compared with the control scenario). 
d The Control, Elim I and Elim II scenarios are described in Kim et al. (99). 
APOC: African Programme for Onchocerciasis Control, GDP: Gross domestic product, OCP: Onchocerciasis Control Programme in West Africa. 
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Table 4. Description of studies investigating the productivity losses associated with onchocerciasis-associated morbidity (adapted from (62)) 
Study Country Year Study design Population Sample size Sequela Definition of productivity loss Results 
Evans (128) Guinea  1995 Observation
al 
(survey) 
Household members 
in a highly endemic 
area. 
319 a) Visual 
impairment 
Self-reported 'inactive' occupational status. a) 38% 
 b) Blindness b) 79% 
Kim et al. 
(129) 
Ethiopia 1997 Case-control Coffee plantation 
workers. 
235 a) OSD 
(intermediate) 
a) Daily wages (individuals infected with OSD 
(intermediate) vs. those without). 
a) 10% 
 b) OSD 
(severe) 
b) Daily wages (individuals infected with OSD 
(severe) vs. those without). 
b) 15% 
Okeibunor et 
al. (130) 
Cameroo
n, DRC, 
Nigeria, 
Uganda 
 Observation
al 
(cross-
sectional) 
Primarily residents 
from villages where 
ivermectin 
distribution was 
ongoing. 
1,600 General 
onchocerciasis 
a) Increase in productivity from ivermectin 
treatment. 
a) 76% 
2011 b) Percentage of respondents that referred ability 
to work better after ivermectin treatment. 
b) 75.6% 
Oladepo et al. 
(131) 
Nigeria 1993 Case-control Male farmers. 102 OSD Farm size that a man can keep satisfactorily 
weeded (workers with vs. without OSD). 
9,117 vs 
13,850 
m2 (34% 
loss) 
Thomson 
(132) 
Cameroo
n 
1971 Case-control Estate workers in an 
onchocerciasis 
endemic area. 
420 Unspecified 
(general) 
Working days (workers with vs. without 
onchocerciasis). 
20% 
Wogu & 
Okaka (133) 
Nigeria 2008 Observation
al (survey) 
Rural farming 
community in a 
mesoendemic area. 
200 a) OSD 
(itching) 
a) Percentage of respondents that reported a 
reduction in strength and concentration at work. 
a) 13.5% 
 b) OSD 
(nodules) 
b) Percentage of respondents that reported a 
decline in sales in business/trading. 
b) 11% 
 c) Visual 
impairment 
(ocular lesions) 
c) Percentage of respondents that reported giving 
up jobs (Productivity loss not specified). 
c) 14% 
Workneh et 
al. (134) 
Ethiopia 1993 Case-control Male permanent 
coffee plantation 
workers. 
196 OSD Absenteeism/sick leave and net monthly pay 
(workers with vs. without OSD). 
25% 
WHO & World 
Bank (70) 
Nigeria, 
Ethiopia, 
Sudan 
1997 Case-control Households in 
hyperendemic 
communities. 
824 OSD Time spent on productive activities (individuals 
with vs. without OSD signs and symptoms). 
Not 
significan
t 
DRC: Democratic Republic of the Congo, OSD: Onchocerciasis-associated skin disease. 
A
cc
ep
te
d 
A
rt
ic
le
 
Table 5: Summary of the assumed productivity losses and disability weights used for onchocerciasis-
associated morbidity 
Study Low vision Blindness Skin disease/ 
troublesome itch 
Source  
Assumed productivity loss 
Benton & Skinner (67) - 100% -  
Kim & Benton (58) - 100% -  
McFarland & Murray (124) Not available Not available Not available  
Benton (125) - Unclear -  
Haddix (69) - Not available -  
Kim et al. (60) Patient: 38% 
Caregiver: 5%  
Patient: 79% 
Caregiver: 10% 
Severe itching: 19% (128, 129, 134-137) 
Redekop et al. (59) 38%  79% Moderate: 10%  
Mild: 0% 
(128, 129) 
 
Healthy life year weightsa    
Prescott et al. (126, 127) - 1.0 -  
Evans et al. (71) - 0.5 -  
Benton (125) - 1.0 -  
DALY weightsa     
GBD 1990 0.245 0.488 (treated) 
0.600 (untreated) 
0.068 GBD 1990 (138) 
GBD 2000 (138)  0.224 (treated) 
0.282 
(untreated) 
0.60 0.068 GBD 2000 (138)  
McFarland & Murray (124) Not available Not available Not available Not available 
Turner et al. (73) 0.170 0.594 0.068 GBD 2004 (139) 
Coffeng et al. (30) 0.282 0.594 0.068 GBD 2004 (139) 
Coffeng et al. (78) 0.033 0.195 0.108b  GBD 2010 (140) 
de Vlas et al. (141) 0.101c  0.101c 0.079b  GBD 2010 (140) 
a Refl ct the severity of the disease sequelae with 0 representing perfect health and 1 representing death.  
b Used a weight representing an overall average for skin disease across more finely disaggregated strata/severity 
levels 
c Used a weight representing an overall average for visual morbidity (i.e. the weight was not stratified by “low 
vision” and “blindness”). 
Where relevant additional studies that were not performing economic evaluations were included for comparison. 
DALYs: Disability-adjusted life years, GBD: Global Burden of Disease Study. 
 
This article is protected by copyright. All rights reserved. 
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Figure 1: Decision tree outlining the inclusion and exclusion of the identified studies. Some studies 
reported both cost-benefit and cost-effectiveness estimates. A PRISMA checklist is provided in 
Supporting Information. 
 
 
Figure 2: The relationship between the prevalence of onchocerciasis-associated blindness and the 
prevalence of skin microfilariae in savannah (A) and forest/mixed forest-savannah settings (B). The 
figures were adapted from Figures S3 and S4 in Coffeng et al. (30). The data were originally taken 
from (142-148).  
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Box 1: Summary of the control programmes. 
 
The Onchocerciasis Control Programme in West Africa (OCP, 1974-2002): The OCP was launched in 1974-
1975, and originally covered a core area in seven countries of West Africa (11). However, by 1990 the OCP 
had expanded its operations to include larger zones and four additional countries following the southern 
and western extensions (10, 11). From 1974 to 1988 the OCP focused on a strategy of weekly aerial 
larviciding of blackfly breeding sites. In 1987 ivermectin was registered for human use against 
onchocerciasis, and due to the suitability of this drug for mass treatment, large-scale chemotherapeutic 
control programmes became feasible (10). Large-scale mass drug administration (MDA) of ivermectin began 
in the OCP regions in the late 1980’s, initially administered by mobile teams of paid, local health 
professionals (10).  
African Programme for Onchocerciasis Control (APOC, 1995-2015): The APOC was initiated in 1995 
including 19 African countries (11, 149). The programme pioneered a community-directed treatment 
approach, within which the local communities rather than health services directed the treatment process; 
the treatments were delivered by volunteer community-directed distributors (CDDs) (149-151). APOC 
gradually expanded and by 2014 it had a network of over 699,656 volunteer CDDs (151). When the 
programme concluded at the end of 2015 it was supporting onchocerciasis control and elimination activities 
in 31 African countries (including the 19 original signatories of the Memorandum, South Sudan, and the 11 
ex-OCP participating countries) (149).  
The Onchocerciasis Elimination Program for the Americas (OEPA, 2002-present): The OEPA started in 1992 
in six countries of the Americas (across 13 discrete foci) (11, 12). The strategy is based on the biannual (twice 
a year) distribution of ivermectin, to all endemic communities (covering at least 85% of the eligible 
population) (12). As of December 2016, a total of four countries have successfully completed the World 
Health Organization process for verification of elimination (152). 
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Box 2: Glossary  
Cost-benefit analysis: A type of economic evaluation which compares the cost of an intervention to its 
monetary benefits. The results are typically expressed as an internal rate of return or net present value. 
Cost-effectiveness analysis: A type of economic evaluation in which the cost of an intervention is compared to 
the quantity of a single non-monetary effectiveness measure (such as the number of deaths or cases averted). 
This avoids the issues associated with monetising the benefits of healthcare interventions. The results are 
expressed as a cost per unit of outcome (see cost-effectiveness ratio). 
Cost-effectiveness ratio: A statistic used to summarise the cost-effectiveness of an intervention. It is calculated 
by dividing the cost of an intervention by its effectiveness measure, such as a cost per disability-adjusted life 
year (DALY) averted or healthy life year gained. An incremental cost-effectiveness ratio is calculated by dividing 
the difference in costs by the difference in effectiveness outcomes of two alternative options (it summaries the 
‘extra cost per additional unit of effect gained’). 
Community-directed distributors (CDDs): Also referred to as community drug distributors, these are volunteers 
selected by their communities to distribute treatment.  
Disability-adjusted life years (DALYs): A measure of disease burden that is calculated as the sum of the years of 
life lost due to premature mortality and the years of healthy life lost due to disability. The number of years of 
healthy life lost due to disability is calculated using a disability weight factor (between 0 and 1) that reflects the 
severity of the disease/disability. One DALY can be thought of as one year of "healthy" life lost. 
Economic costs (opportunity costs): These define the cost of a resource as its value in its next best alternative 
use (also known as an opportunity cost). This is a broader conceptualization of a resource’s value than its 
financial cost, as it recognizes that using a resource makes it unavailable for productive use elsewhere. The 
rationale behind economic costs is that they are intended to represent the full value of all the resources used for 
an intervention, and they account for the fact that resources can have a value that is not (fully) captured by their 
financial costs (such as the ‘free’ use of building space provided by Ministries of Health, and the unpaid time 
devoted to mass drug administration by volunteer CDDs). This is particularly important when considering issues 
related to the sustainability and replicability of interventions. 
Economies of scale: The reduction in the average cost per unit resulting from increased production/output; in 
this case, the reduction in the cost per treatment as a result of increasing the number of people treated. 
Economies of scope: The reduction in the average cost per unit resulting when providing multiple 
goods/services jointly; in this case, the reduction in the cost per treatment when delivering more than one 
intervention at once (e.g. integrated control programmes or using the CDD platform to deliver more than a 
single intervention). Examples include administering treatment for both schistosomiasis and soil-transmitted 
helminthiases within the same programme (instead of by separate vertical programmes). 
Financial costs: The actual expenditure (i.e. the amount paid) for the goods, resources and services that are 
purchased.  
Friction cost approach: The approach that takes the employer's perspective for valuing lost productivity, and 
therefore only counts as lost, the hours not worked by a sick employee before another employee takes over the 
work (65). It is based on the assumption that an ill individual will eventually be replaced by another healthy 
worker – therefore, the initial productivity levels are restored after this ‘friction period’. 
Human capital approach: The approach that takes the patient's perspective for valuing lost productivity and 
therefore counts all the work they miss, as a productivity loss. With this approach, all potential production not 
performed by an individual because of morbidity or premature mortality is counted as a production loss (65). 
Indirect costs (productivity costs): Indirect cost represents the value of productivity losses that result from 
illness, treatment, or premature death.  
Internal rate of return (IRR): The discount rate applied to the monetised benefits and costs of an intervention, 
that makes its net present value equal to zero. Also known as the economic rate of return (ERR). 
Mass drug administration (MDA): The large-scale distribution of drugs to eligible people within populations at 
risk of infection, irrespective of current individual infection status, i.e. without the need for screening for or 
diagnosing infection prior to each treatment round.  
Net present value (NPV): The difference between an intervention’s monetised benefits and its cost. A positive 
NPV is an indicator of a successful investment. 
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Perspective: The viewpoint from which the intervention’s costs and consequences are evaluated. When 
adopting the healthcare providers perspective, the costs falling outside the healthcare sector are ignored. In 
contrast, when adopting the societal perspective, all relevant cost categories should be included, including those 
incurred by the patients. 
Time horizon: The time horizon for the analysis; the duration over which outcomes and costs are calculated. 
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Box 3: Discounting 
 
Healthcare interventions typically incur costs and generate health outcomes over a number of years. 
However, society does not place an equal value on costs or health outcomes that occur now compared 
to those that occur in the future. This is because there is an opportunity cost to spending money (as it 
could be invested to yield returns) and a desire to have benefits now rather than in the future. Economic 
evaluations therefore need to weight differently costs and health outcomes that occur in the future. 
Discounting is the process used to convert costs or health outcomes occurring in the future into a 
present value (153-155). It makes costs and benefits occurring in the future worth less than those in the 
present. This allows the comparison of the costs and outcomes occurring over different time periods. 
The discount rate determines the strength of the time preference – the higher the discount rate the 
lower the value placed on future costs/outcomes. Note that adjusting for inflation (which accounts for 
the fact that the purchasing power of a currency changes over time) is not the same as discounting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When different analyses have used different discount rates, it makes the results harder to compare 
them directly. The WHO’s guide to cost-effectiveness analysis recommends using a 3% discount rate for 
both costs and health outcomes (and testing the sensitivity of the results to using a 0% discount rate for 
health effects and a 6% discount rate for costs within the sensitivity analysis) (50). These 
recommendations have engendered greater consistency in the use of discount rates. However, although 
using the 3% discount rate has become the standard, there is still debate within the field, particularly on 
discounting of health effects (154, 155). 
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